Compare HNRG & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNRG | DSGN |
|---|---|---|
| Founded | 1949 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 763.0M | 819.6M |
| IPO Year | 1995 | 2021 |
| Metric | HNRG | DSGN |
|---|---|---|
| Price | $19.66 | $12.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $25.38 | $15.25 |
| AVG Volume (30 Days) | 647.0K | ★ 881.5K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $469,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.09 | N/A |
| 52 Week Low | $14.68 | $3.33 |
| 52 Week High | $24.70 | $17.25 |
| Indicator | HNRG | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.35 | 58.30 |
| Support Level | $18.89 | $11.94 |
| Resistance Level | $20.68 | $13.54 |
| Average True Range (ATR) | 1.06 | 0.63 |
| MACD | 0.07 | 0.24 |
| Stochastic Oscillator | 89.09 | 88.26 |
Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.